About Us


Recent Headlines

Sonoran Biosciences  |  1475 N. Scottsdale Rd. Suite 200  |  Scottsdale, AZ 85257  |  P: 480-389-6413

© 2016 Sonoran Biosciences, Inc.

Sonoran Biosciences has received a $1,484,417 Phase 2 SBIR grant from the National Institutes of Health. See the press release.

Sonoran Biosciences has been accepted as a presenting company at the 2016 AZBio White Hat Life Science Investor Conference.

A study including authors from Sonoran Biosciences has been published in Clinical Orthopaedics and Related Research indicating increased susceptibility of bacterial biofilms with multi-day antimicrobial exposure.


Sonoran Biosciences is a privately held early stage pharmaceutical company that has developed SB Gel, a novel viscous sustained release carrier. SB Gel enables sustained release of a wide variety of drugs to new sites in the body, including surgical sites, device surfaces, and healing tissues. We develop new formulations using approved active ingredients, requiring reduced development cost and risk while retaining the exclusivity of a typical pharmaceutical. Formulations based on SB Gel have potential in a number of therapeutic areas including infection, pain management, and osteoarthritis. Our first product, SB Gel with a combination of tobramycin and vancomycin, is being developed for treatment of prosthetic joint infection.